# Pathophysiology of Diabetes Mellitus

## Normal Glucose Metabolism

### Glucose Homeostasis Regulation
- **Plasma glucose range**: 70-140 mg/dL (fasting)
- **Regulation mechanisms**:
  - Hormonal control (insulin, glucagon, cortisol, catecholamines)
  - Neural regulation (hypothalamic centers)
  - Substrate utilization (glucose, fatty acids, amino acids)

### Role of Insulin
- **Source**: Pancreatic β-cells of islets of Langerhans
- **Primary actions**:
  - Glucose uptake in muscle and adipose tissue
  - Glycogen synthesis in liver and muscle
  - Protein synthesis and lipogenesis
  - Inhibition of glycogenolysis and gluconeogenesis

### Insulin Secretion Dynamics
- **Basal insulin**: Continuous secretion for metabolic needs
- **Prandial insulin**: Meal-stimulated secretion
- **Two-phase response**:
  - First phase: Immediate response (acute insulin release)
  - Second phase: Sustained release (main secretory response)

## Pathogenesis of Type 1 Diabetes Mellitus

### Autoimmune Destruction Process
- **Primary defect**: Destruction of β-cells by autoimmune process
- **Precipitating factors**:
  - Genetic susceptibility (HLA-DR3/DR4)
  - Environmental triggers (viral infections, toxins)
  - Loss of self-tolerance

### Stages of β-Cell Destruction
1. **Genetic predisposition**: HLA and non-HLA genes
2. **Triggering event**: Viral infection or environmental insult
3. **Active autoimmunity**: Islet cell antibodies appear
4. **β-cell dysfunction**: Insulin secretion declines
5. **Overt diabetes**: Absolute insulin deficiency

### Immunological Markers
- **Islet cell autoantibodies (ICA)**
- **Insulin autoantibodies (IAA)**
- **GAD antibodies (GADA)**
- **IA-2 antibodies**
- **ZnT8 antibodies**
- **C-peptide levels**: Low or undetectable

### Histopathology
- **Inflammatory infiltrate**: Lymphocytes and macrophages
- **β-cell apoptosis**: Progressive cell loss
- **Islet fibrosis**: Late stage destruction
- **Residual β-cells**: Few remaining functional cells

## Pathogenesis of Type 2 Diabetes Mellitus

### Insulin Resistance
- **Primary defect**: Impaired insulin action at target tissues
- **Mechanism**:
  - Post-receptor signaling defects
  - Reduced glucose transporter (GLUT4) translocation
  - Impaired glycogen synthase activity
  - Increased lipolysis and free fatty acids

### Progressive β-Cell Failure
- **Compensatory hyperinsulinemia**: Initial response to insulin resistance
- **β-cell exhaustion**: Progressive decline in insulin secretion
- **Glucose toxicity**: Chronic hyperglycemia worsens β-cell function
- **Lipotoxicity**: Excess fatty acids damage β-cells

### The Twin Defects Model
- **Early stage**: Insulin resistance predominant
- **Late stage**: β-cell failure becomes critical
- **Time course**: Insulin resistance precedes β-cell failure by years
- **Interaction**: Insulin resistance accelerates β-cell exhaustion

### Role of Obesity
- **Central obesity**: Visceral fat accumulation
- **Adipokines**: Altered leptin and adiponectin secretion
- **Inflammation**: Chronic low-grade inflammation
- **FFA flux**: Increased fatty acid mobilization
- **Insulin signaling**: Impaired in multiple tissues

## Role of Insulin Resistance

### Mechanisms of Insulin Resistance
1. **Receptor level**: Impaired insulin binding
2. **Post-receptor**: Dysfunctional signaling pathways
3. **Glucose transport**: GLUT4 dysfunction
4. **Hepatic glucose output**: Uncontrolled gluconeogenesis

### Contributing Factors
- **Obesity**: Central fat distribution
- **Physical inactivity**: Reduced insulin sensitivity
- **Aging**: Progressive insulin resistance
- **Genetic factors**: Multiple gene polymorphisms

### Tissue-Specific Effects
- **Muscle**: Reduced glucose uptake
- **Liver**: Increased gluconeogenesis
- **Adipose tissue**: Impaired insulin-mediated antilipolysis
- **Pancreas**: β-cell compensatory response

## β-Cell Dysfunction

### Functional Defects
- **First-phase insulin secretion**: Lost early in T2DM
- **Proinsulin processing**: Impaired cleavage
- **Secretory granules**: Reduced number and function
- **Calcium signaling**: Abnormal intracellular calcium

### Morphological Changes
- **Amyloid deposition**: Islet amyloid polypeptide (IAPP)
- **Lipid accumulation**: Intracellular triglycerides
- **Apoptosis**: Programmed cell death
- **Fibrosis**: Extracellular matrix changes

### Glucotoxicity
- **Mechanism**: Chronic hyperglycemia impairs β-cell function
- **Oxidative stress**: ROS generation via glucose autoxidation
- **ER stress**: Protein misfolding and unfolded protein response
- **Gene expression**: Altered transcription factors

### Lipotoxicity
- **Mechanism**: Excess fatty acids cause β-cell damage
- **Lipid metabolites**: Ceramides and diacylglycerols
- **Inflammasome activation**: Cytokine production
- **Apoptosis pathways**: Mitochondrial and ER pathways

## Additional Pathogenic Factors

### Inflammation
- **Chronic low-grade inflammation**: Elevated cytokines (TNF-α, IL-6)
- **CRP levels**: Marker of inflammation
- **Endothelial dysfunction**: Vascular complications
- **Macrophage infiltration**: Adipose tissue inflammation

### Oxidative Stress
- **Free radical production**: Hyperglycemia-induced
- **Antioxidant depletion**: Reduced glutathione and vitamins
- **Mitochondrial dysfunction**: Impaired ATP production
- **DNA damage**: Increased mutation rates

### Endothelial Dysfunction
- **Early marker**: Impaired vasodilation
- **Mechanism**: Reduced NO production
- **Consequence**: Atherosclerosis progression
- **Link to complications**: Micro- and macrovascular disease

### Genetic Factors
- **Monogenic forms**: MODY, mitochondrial diabetes
- **Polygenic inheritance**: Multiple risk alleles
- **Epigenetic changes**: Gene expression modifications
- **Gene-environment interaction**: Environmental triggers

## Pathophysiology Summary

### Type 1 DM
```
Autoimmune destruction → β-cell destruction → Absolute insulin deficiency → Hyperglycemia
```

### Type 2 DM
```
Genetic predisposition + Environmental factors → Insulin resistance + β-cell dysfunction → Relative insulin deficiency → Hyperglycemia
```

### Common Pathways
- **Hyperglycemia**: Initiates glucotoxicity
- **Lipotoxicity**: Fatty acids worsen β-cell failure
- **Oxidative stress**: Damages multiple cell types
- **Inflammation**: Amplifies tissue damage

## Learning Objectives
- Understand normal glucose homeostasis
- Describe pathogenesis of Type 1 DM
- Explain mechanisms of Type 2 DM
- Recognize role of insulin resistance
- Understand β-cell failure processes
- Integrate pathophysiology with clinical presentation
